Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease
jRCT2080223165Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label trial of vedolizumab in autoimmune colitis and Crohn's disease (2 arms), sponsored by Takeda. Started Apr 2016; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on jRCT2080223165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223165.